Escherichia coli
doxorubicin
strain
WO153
isolate
NA
host
NA
isolation_source
NA
collection_date
2016/2018
geo_loc_name
NA
altitude
NA
biomaterial_provider
NA
culture_collection
NA
depth
NA
env_broad_scale
NA
genotype
NA
host_tissue_sampled
NA
identified_by
NA
lab_host
NA
lat_lon
NA
mating_type
NA
passage_history
NA
samp_size
NA
serotype
NA
serovar
NA
specimen_voucher
NA
temp
NA
sample_type
cell culture
id_espinoza-et-al
doxorubicin|dmso-10|-2|3|10.0|33|s33
run
10.0
id_jira
SOLEXASEQ-1137
id_orourke-et-al
R10_Doxorubicin_BR3
id_sequencing-number
S33
id_barcode-number
33
biological_replicate
3
sample-category
nuisance_compound
sample-category_encoding
-2
cpd_local
doxorubicin
cpd_universal
doxorubicin
ctrl_local
dmso-10
ctrl_universal
dmso
og_moa
nuisance
moa
nuisance
moa_encoding
-2
moa_color
#d3d3d3
neu_sub-moa
toxin
neu_sub-moa_encoding
3.0
gene_target_description
For the purposes of this project, I would classify it as a nuisance compound along with CCCP and SDS. We come across doxorubicin fairly frequently as it is made by Streptomyces. It intercalates into DNA – and as a result, inhibits DNA synthesis. DNA intercalators do not make good antibiotics because the target isn't specific to bacteria. Just like, SDS kills bacteria but its mechanism isn't specific to bacteria. We consider all DNA intercalators to be nuisance compounds, but this one is especially frustrating because it is very potent. We can detect activity when it is present at very low levels and it can require a lot of volume of active culture to figure out that the active compound is doxorubicin.
ORourke_et_al
True
Espinoza_et_al
False
BioSampleModel
Microbe, viral or environmental